The authors reply

Affiliations

¹ Department of Emergency Medicine and Department of Infectious Diseases, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
² Department of Emergency and Intensive Care Medicine, JA Hiroshima General Hospital, Hatsukaichi, Japan.
³ Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
⁴ Centre for Heart Lung Innovation, St. Paul's Hospital, The University of British Columbia, Vancouver, BC, Canada.
⁵ Department of Pharmacoepidemiology, Kyoto University, Kyoto, Japan.
⁶ Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
⁷ Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan.
⁸ Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan.

Kenji Kubo et al. Crit Care Med. 2025.

. 2025 Feb 1;53(2):e525-e526.

doi: 10.1097/CCM.0000000000006565. Epub 2025 Feb 21.

¹ Department of Emergency Medicine and Department of Infectious Diseases, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
² Department of Emergency and Intensive Care Medicine, JA Hiroshima General Hospital, Hatsukaichi, Japan.
³ Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
⁴ Centre for Heart Lung Innovation, St. Paul's Hospital, The University of British Columbia, Vancouver, BC, Canada.
⁵ Department of Pharmacoepidemiology, Kyoto University, Kyoto, Japan.
⁶ Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
⁷ Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan.
⁸ Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan.

No abstract available

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

1. Robert A, Perriens E, Blackman S, et al.: In sepsis, procalcitonin-guided antibiotic discontinuation strategies may be beneficial and safe: Beware of potential confounders. Crit Care Med. 2025; 53:e523–e524
1. Kubo K, Sakuraya M, Sugimoto H, et al.: Benefits and harms of procalcitonin- or C-reactive protein-guided antimicrobial discontinuation in critically ill adults with sepsis: A systematic review and network meta-analysis. Crit Care Med. 2024; 52:e522–e534
1. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al.: Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021; 203:202–210
1. Bloos F, Trips E, Nierhaus A, et al.; for SepNet Critical Care Trials Group: Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: A randomized clinical trial. JAMA Intern Med. 2016; 176:1266–1276
1. Heilmann E, Gregoriano C, Wirz Y, et al.: Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: A patient-level meta-analysis from randomized controlled trials. Clin Chem Lab Med. 2021; 59:441–453